The thickened left ventricle: Etiology, differential diagnosis and implications for cardiovascular radiology;Der dicke linke Ventrikel: Ursachen und Differenzialdiagnose der linksventrikulären Hypertrophie und Implikationen für die kardiovaskuläre Radiologie

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 184, Issue 8, 2012, Pages 697-705

  Bischoff, P ^a   Radke, P W ^b   Barkhausen, J ^a   Hunold, P ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Medizinische Klinik II   (Germany)

Author keywords

heart; hyperplasia hypertrophy; MR imaging

Indexed keywords

ALGORITHM; ARTICLE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; IMAGE ANALYSIS; PRIORITY JOURNAL; RADIOCARDIOGRAPHY;

CARDIOMYOPATHIES; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; HEART SEPTUM; HEART VENTRICLES; HEMODYNAMICS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; ORGAN SIZE; REFERENCE VALUES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84864739672     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0032-1312891     Document Type: Article

References (77)

1. Bottini PB, Carr AA, Prisant LM et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens: 1995; 8 221 228
2. Semelka RC, Tomei E, Wagner S et al. Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. Am Heart J: 1990; 119 1367 1373 (Pubitemid 20215623)
3. Hunold P, Vogt FM, Heemann UW et al. Myocardial mass and volume measurement of hypertrophic left ventricles by MRI-study in dialysis patients examined before and after dialysis. J Cardiovasc Magn Reson: 2003; 5 553 561 (Pubitemid 37420770)
4. Levy D, Garrison R, Savage D et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med: 1990; 322 1561 1566 (Pubitemid 20176696)
5. Böcker W, Denk H, Heitz PU. Pathologie. München Urban & Fischer: 2004; 442 443
6. Bove KE, Rowlands DT, Scott RC. Observations on the assessment of cardiac hypertrophy utilizing a chamber partition technique. Circulation: 1966; 33 558 568
7. Hudsmith LE, Petersen SE, Francis JM et al. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson: 2005; 7 775 782 (Pubitemid 41770055)
8. Aurigemma GP, Silver KH, Priest MA et al. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol: 1995; 26 195 202
9. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation: 1993; 88 1444 1455 (Pubitemid 23296890)
10. Koren MJ, Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med: 1991; 114 345 352
11. Bolte HD, Autenrieth G, Böhm M et al. Entzündliche Herzerkrankungen und Kardiomyopathien. In: Erdmann E, Riecker G. (eds) Klinische Kardiologie: Krankheiten des Herzens, des Kreislaufs und der Gefäße. Berlin; Heidelberg Springer: 1996; 279 285
12. Katus HA, Vosberg HP. Die Herzinsuffizienz als genetische Krankheit: Beispiel Kardiomyopathie. Internist: 1993; 34 902 911 (Pubitemid 23305360)
13. Bolte HD, Autenrieth G, Böhm M et al. Entzündliche Herzerkrankungen und Kardiomyopathien. In: Erdmann E, Riecker G. (eds) Klinische Kardiologie: Krankheiten des Herzens, des Kreislaufs und der Gefäße. Berlin; Heidelberg Springer: 1996; 256 258
14. Hergan K, Schuster A, Mair M et al. Normalwerte der Herzdurchmesser in der Cine-MRT. Fortschr Röntgenstr: 2004; 176 1599 606 (Pubitemid 39486491)
15. Pennell DJ. Ventricular volume and mass by CMR. J Cardiovasc Magn Reson: 2002; 4 507 513 (Pubitemid 36083962)
16. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med: 1916; 17 863 871
17. Prisant LM. Hypertensive heart disease. J Clin Hypertens: 2005; 7 231 238
18. Nkomo VT, Gardin JM, Skelton TN et al. Burden of valvular heart diseases: a population-based study. Lancet: 2006; 368 1005 1011 (Pubitemid 44353666)
19. Roberts WC. Valvular, subvalvular and supravalvular aortic stenosis. Morphologic features. Cardiovasc Clin: 1973; 5 97
20. Dahl J, Flachskampf FA, Hoffmann R et al. Erworbene Herzklappenfehler. In: Erdmann E, Riecker G. (eds) Klinische Kardiologie: Krankheiten des Herzens, des Kreislaufs und der Gefäße. Berlin; Heidelberg Springer: 1996; 376 385
21. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy causes. Am J Cardiol: 1970; 26 72
22. McMillan IKR. Aortic stenosis: A postmortem cinephotographic study of valve action. Br Heart J: 1955; 17 56
23. Schlosser T, Malyar N, Jochims M et al. Quantification of aortic valve stenosis in MRI-comparison of steady-state free precession and fast low-angle shot sequences. Eur Radiol: 2007; 17 1284 1290 (Pubitemid 46691959)
24. Bonow RO, Carabello BA, Kanu C. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation: 2006; 114 e84 e231 (Pubitemid 44268973)
25. Lewin MB, Otto CM. The bicuspid aortic valve: adverse outcomes from infancy to old age. Circulation: 2005; 111 832 834 (Pubitemid 40279882)
26. Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol: 2006; 47 2141 2151 (Pubitemid 43795057)
27. Antonini-Canterin F, Huang G, Cervesato E et al. Symptomatic aortic stenosis: does systemic hypertension play an additional role? Hypertension: 2003; 41 1268 1272 (Pubitemid 36706076)
28. Dahl J, Flachskampf FA, Hoffmann R et al. Erworbene Herzklappenfehler. In: Erdmann E, Riecker G. (eds) Klinische Kardiologie: Krankheiten des Herzens, des Kreislaufs und der Gefäße. Berlin; Heidelberg Springer: 1996; 378
29. Pouleur AC, le Polain de Waroux JB, Pasquet A et al. Planimetric and continuity equation assessment of aortic valve area: Head to head comparison between cardiac magnetic resonance and echocardiography. J Magn Reson Imaging: 2007; 26 1436 1443 (Pubitemid 350291270)
30. Williams JC, Barrat-Boyes BG, Lowe JB. Supravalvular aortic stenosis. Circulation: 1961; 24 1311 1318
31. Beuren AJ, Apitz J, Harmjanz D. Supravalvular aortic stenosis in association with mental retardation and a certain facial appearance. Circulation: 1962; 26 1235 1240
32. Brand A, Keren A, Reifen RM et al. Echocardiographic and Doppler findings in the Williams syndrome. Am J Cardiol: 1989; 63 633 635 (Pubitemid 19070129)
33. Wren C, Oslizlok P, Bull C. Natural history of supravalvular aortic stenosis and pulmonary artery stenosis. J Am Coll Cardiol: 1990; 15 1625 1630 (Pubitemid 20174327)
34. Summers RM, Andrasko-Bourgeois J, Feuerstein IM et al. Evaluation of the aortic root by MRI: insights from patients with homozygous familial hypercholesterolemia. Circulation: 1998; 98 509 518 (Pubitemid 28371248)
35. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol: 2002; 39 1890 1900 (Pubitemid 34628268)
36. Sampayo F, Pinto FF. The sex distribution of congenital cardiopathies. Acta Med Port: 1994; 7 413 418
37. Tawes RL Jr, Berry CL, Aberdeen E. Congenital bicuspid aortic valves associated with coarctation of the aorta in children. Br Heart J: 1969; 31 127 128
38. Boxer RA, LaCorte MA, Singh S et al. Nuclear magnetic resonance imaging in evaluation and follow-up of children treated for coarctation of the aorta. J Am Coll Cardiol: 1986; 7 1095 1098 (Pubitemid 16103107)
39. Baker EJ, Ayton V, Smith MA et al. Magnetic resonance imaging of coarctation of the aorta in infants: use of a high field strength. Br Heart J: 1989; 62 97 101 (Pubitemid 19199409)
40. Miabi Z, Pourfathi H, Midia M et al. Comparison of ct angiography and digital substraction angiography in the diagnosis of aortic coarction. Pak J Biol Sci: 2011; 14 74 77
41. Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation: 2006; 113 1807 16 (Pubitemid 43958474)
42. Meurs KM, Mealey KL. Evaluation of the flanking nucleotide sequences of sarcomeric hypertrophic cardiomyopathy substitution mutations. Mutat Res: 2008; 642 86 89
43. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA: 2002; 287 1308 1320 (Pubitemid 34250486)
44. Maron BJ, McKenna WJ, Danielson GK et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol: 2003; 42 1687 1713 (Pubitemid 37383745)
45. Spirito P, Bellone P, Harris KM et al. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med: 2000; 342 1778 1785 (Pubitemid 30390237)
46. Maron BJ, Estes NAM III, Maron MS et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation: 2003; 107 2872 2875 (Pubitemid 36736624)
47. Maron BJ. Sudden death in young athletes. N Engl J Med: 2003; 349 1064 1075 (Pubitemid 37098275)
48. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardi ography in 600 patients. J Am Col l Cardiol: 1995; 26 1699 1708
49. Maron BJ, Gottdiener JS, Bonow RO et al. Hypertrophic cardiomyopathy with unusual locations of left ventricular hypertrophy undetectable by M-mode echocardiography: identification by wide-angle, two-dimensional echocardiography. Circulation: 1981; 63 409 418 (Pubitemid 11168760)
50. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of the distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide-angle, two-dimensional echocardiographic study of 125 patients. Am J Cardiol: 1981; 48 418 428 (Pubitemid 11014383)
51. Schulz-Menger J, Abdel-Aty H, Busjahn A et al. Left ventricular outflow tract planimetry by cardiovascular magnetic resonance differentiates obstructive from non-obstructive hypertrophic cardiomyopathy. J Cardiovasc Magn Reson: 2006; 8 741 746 (Pubitemid 44195996)
52. Henry WL, Clark CE, Griffith JM et al. Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis). Am J Cardiol: 1975; 35 337 345
53. Sondergaard L, Ståhlberg F, Thomsen C. Magnetic resonance imaging of valvular heart disease. J Magn Reson Imaging: 1999; 10 627 638 (Pubitemid 29519764)
54. Rickers C, Wilke NM, Jerosch-Herold M et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation: 2005; 112 855 861 (Pubitemid 41170072)
55. Sohns C, Sossalla S, Schmitto JD et al. Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography. Clin Res Cardiol: 2010; 99 359 368
56. Kim RJ, Albert TS, Wible JH et al. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation: 2008; 117 629 637
57. Hunold P, Schlosser T, Vogt FM et al. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. Am J Roentgenol: 2005; 184 1420 1426 (Pubitemid 43821809)
58. Simonetti OP, Kim RJ, Fieno DS et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology: 2001; 218 215 223 (Pubitemid 32151298)
59. Kellman P, Arai AE, McVeigh ER et al. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med: 2002; 47 372 383 (Pubitemid 34116807)
60. Kellman P, Larson AC, Hsu LY et al. Motion-corrected free-breathing delayed enhancement imaging of myocardial infarction. Magn Reson Med: 2005; 53 194 200 (Pubitemid 40110492)
61. Bogaert J, Goldstein M, Tannouri F et al. Original report. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. Am J Roentgenol: 2003; 180 981 985 (Pubitemid 36363036)
62. Moon JC, Reed E, Sheppard MN et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol: 2004; 43 2260 2264 (Pubitemid 38757595)
63. Moon JC, McKenna WJ, McCrohon JA et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol: 2003; 41 1561 1567 (Pubitemid 36543376)
64. Adabag AS, Maron BJ, Appelbaum E et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol: 2008; 51 1369 1374 (Pubitemid 351443083)
65. Maron MS, Maron BJ, Harrigan C et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol: 2009; 54 220 228
66. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood: 1986; 68 220 224 (Pubitemid 16033633)
67. Arbustini E, Gavazzi A, Merlini G. Fibril-forming proteins: the amyloidosis: new hopes for a disease that cardiologists must know. Ital Heart J Suppl: 2002; 3 590 597 (Pubitemid 34803522)
68. Nihoyannopoulos P. Amyloid heart disease. Current Opin Cardiol: 1987; 2 371 376
69. Laurent M, Toulet R, Ramée MP et al. Light chain disease with terminal myocardiopathy. Arch Mal Coeur Vaiss: 1985; 78 943 946 (Pubitemid 15069545)
70. Yazaki M, Tokuda T, Nakamura A et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun: 2000; 274 702 706 (Pubitemid 30663682)
71. Ishikawa Y, Ishii T, Masuda S et al. Myocardial ischemia due to vascular systemic amyloidosis: a quantitative analysis of autopsy findings on stenosis of the intramural coronary arteries. Pathol Int: 1996; 46 189 194 (Pubitemid 26171390)
72. Maceira AM, Joshi J, Prasad SK et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation: 2005; 111 186 193 (Pubitemid 40139730)
73. Nakao S, Takenaka T, Maeda M et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med: 1995; 333 288 293
74. Sachdev B, Takenaka T, Teraguchi H et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation: 2002; 105 1407 1411 (Pubitemid 34263268)
75. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A eficiency: Fabry disease. In: Scriver CR. (ed) The metabolic and molecular basis of inherited disease. New York McGraw-Hill: 2001; 3733 3774
76. Teraguchi H, Takenaka T, Yoshida A et al. End-stage cardiac manifestations and autopsy findings in patients with cardiac Fabry disease. J Cardiol: 2004; 43 98 99
77. Weidemann F, Niemann M, Breunig F et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation: 2009; 119 524 529